截至2025年11月14日收盘，迈瑞医疗(300760)报收于207.7元，下跌0.24%，换手率0.43%，成交量5.17万 手，成交额10.8亿元。 当日关注点 交易信息汇总资金流向 11月14日主力资金净流出646.51万元；游资资金净流入483.43万元；散户资金净流入163.08万元。 大宗交易 投资者： 联影医疗去年的研发投入占收入比为17%，国外如直觉外科为13.5%，世界排名第十的波士顿 科学为11%，其它友商基本都在10%以上，公司做为医疗高科技领域的追赶者，想要5年内冲进世界前 十，困难重重，不加大研发投入是根本不可能的，目前10%左右的研发投入是否太少了，公司是有进一 步加大研发投入的计划？ 董秘： 您好，谢谢关注。迈瑞是全球领先、创新驱动的世界级医疗器械企业及医疗数智化引领者。我 们始终坚持以研发创新为核心驱动力，持续加大投入，依托深厚的技术实力以及对临床需求的深刻洞 察，不断引领并推出契合市场的前沿产品。公司坚持研发高投入，即使在营收规模快速增长的情况下， 依然坚持将每年营收的约10%投入研发，研发投入比例和规模均在医疗器械企业中处于领先地位。截至 2025年三季度末，公司自2018 ...

经历14天12连板后，合富中国(603122.SH)拟停牌核查。 11月14日晚间，合富中国发布公告称，经向上海证券交易所申请，公司股票将于11月17日开市起停牌， 预计停牌时间不超过3个交易日，公司股票将自披露核查公告后复牌。 近期，合富中国成为新"妖股"。10月28日至11月14日期间，其股票连续十四个交易日中有十二个交易日 以涨停价收盘，并5次触及股价异常波动、3次触及严重异常波动情形，期间累计涨幅高达256.29%。 合富中国 v ▼ 603122 L1 市值 94.74亿 量比 1.42 高 24.31 23.80 作 流通 94.74亿 换 28.48% 20.15 1.70 7.69% 市盈™ 亏损 26.18亿 开 21.62 额 同在顺 龙虎榜:11-14入选,净买入1325万元;买 ... X 博诺 分时 日K 周K 月K 五日 更多▲ (0 120分 30分 60分 15分 5分 1分 日线 M5:20.17 M10:16.66 M20:12.01 除权 筹码 均线 ▼ M30:10.14 24.31 25.11 20.16 15.22 10.27 6.12 2025-09-3010-1 ...

Core Viewpoint - Mindray Medical (300760) has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and JPMorgan as joint sponsors [1] Company Overview - Mindray Medical is a leading global medical device company, holding a top position in both market capitalization and industrial revenue within the Chinese medical device industry [1] - The company ranks 23rd among the world's top medical device companies and is the only Chinese enterprise in the top 30 [1] - Mindray has developed a comprehensive product matrix covering various clinical scenarios, with six product categories ranking in the global top three and nine categories leading in China [1] Business Model and Strategy - Mindray is the only company among the top 30 medical device firms that spans multiple product lines, including in vitro diagnostics, life information and support, medical imaging, minimally invasive surgery, and minimally invasive intervention [1] - The company is accelerating its transition to a sustainable growth model driven by a flow-based business (reagents, high-value consumables, and digital services), focusing on an ecosystem centered around equipment, IT, and AI [1] - Mindray is a leader in the field of medical digitalization, possessing the largest hardware ecosystem globally and the most valuable data resources, having successfully launched several medical large models [1] Market Growth Potential - The global medical device market is expected to continue growing, increasing from $456.6 billion in 2020 to $1,157.6 billion by 2035 [1] - As the second-largest medical device market globally, China's market is projected to grow to 1,813.4 billion RMB by 2035, driven by the expansion of grassroots medical services, the popularization of chronic disease management, and government support for innovation and device upgrades [1]

Company Overview - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray) has submitted an application to list on the Hong Kong Stock Exchange, with Huatai International and JPMorgan serving as joint sponsors [1] - Mindray is recognized as a leading global medical device company and a pioneer in medical digitization, with a projected market value in 2024 exceeding that of major domestic competitors combined [4][12] - The company ranks 23rd among the world's top medical device companies and is the only Chinese company in the top 30, achieving this status in a remarkably short time [4] Product and Market Position - Mindray has established a comprehensive product matrix covering multiple product lines, including in vitro diagnostics, life information and support, medical imaging, minimally invasive surgery, and interventional procedures [5] - The company leads the market in several categories, with six product lines ranked in the global top three and nine in the top position within China [4][5] - Mindray is the only top-tier medical device company with a product range that spans various clinical scenarios, including emergency, operating rooms, intensive care, and general wards [4] Strategic Initiatives - The company is transitioning towards a sustainable growth model centered on recurring revenue streams, focusing on equipment, IT, and AI integration [5][6] - Mindray is expanding its business structure from one-time equipment sales to a sustainable, repeat-purchase revenue model, enhancing its growth prospects [6] - The company has launched several advanced AI models in critical care and perioperative medicine, positioning itself at the forefront of medical digitization [6] Financial Performance - Mindray's projected revenues for 2022, 2023, 2024, and the first half of 2025 are approximately RMB 30.37 billion, RMB 34.93 billion, RMB 36.73 billion, and RMB 16.74 billion, respectively [7] - The company's profits for the same periods are estimated at RMB 9.61 billion, RMB 11.58 billion, RMB 11.74 billion, and RMB 5.23 billion [8] - The gross profit margins for these years are 62.2%, 64.2%, 63.1%, and 61.7%, indicating a stable profitability trend [9] Industry Overview - The global medical device market is expected to grow from USD 45.66 billion in 2020 to USD 62.30 billion in 2024, with a CAGR of 8.1% [11] - The Chinese medical device market is projected to increase from RMB 729.8 billion in 2020 to RMB 941.7 billion in 2024, with a CAGR of 6.6% [12] - Structural healthcare demand, technological integration, and supportive policy frameworks are driving the continuous growth of the medical device industry [15][17]

智通财经APP获悉，据港交所11月10日披露，深圳迈瑞生物医疗电子股份有限公司(以下简称：迈瑞医 疗,300760.SZ)递表港交所主板，华泰国际、摩根大通为其联席保荐人。 该公司是医疗数智化领域的引领者。凭借该公司广泛的全球装机基础及与领先医疗机构的长期合作关 系，该公司积累及消化了大量高质量数据。这使该公司拥有全球规模最大的硬件生态系统及最有价值的 数据资源，为该公司的设备+IT+AI生态系统奠定了独特优势。通过与临床医生的密切合作，该公司不 断深化对多个科室及场景中真实实践的理解，这进而推动迈瑞数智医疗生态系统的持续升级。与此同 时，该公司成功发布了启元重症医学大模型，这是全球首个真正实现临床落地的重症医学大模型，并于 近期发布了启元围术期医学大模型、启元医工大模型、启元妇产大模型和启元乳腺大模型。顺应人工智 能与医疗数智化快速发展的浪潮，该公司正加速迈向世界领先的医疗器械企业。 财务资料 收入： 2022年至2024年以及截至2025年6月30日止六个月，该公司收入分别约为303.66亿元、349.32亿元、 367.26亿元及167.43亿元人民币。 据招股书，该公司是全球领先、创新驱动的世界级医疗 ...

Core Insights - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Huatai International and JPMorgan as joint sponsors [1] - The company is recognized as a global leader and innovator in the medical device industry, with a projected market value in 2024 that exceeds the combined value of the second to fifth largest domestic competitors in China [1] - Mindray ranks 23rd among the top global medical device companies and is the only Chinese company in the top 30, achieving this status faster than any other company since its establishment [1] Industry Position - According to Frost & Sullivan, Mindray is the only company among the top global medical device firms that covers a comprehensive range of medical scenarios, including emergency, operating rooms, intensive care units, general wards, and various specialties such as surgery, cardiology, laboratory, and ultrasound [1] - The company holds leading positions in multiple fields, with six product categories ranked among the top three globally and nine product categories holding the number one market share in China, based on projected revenues for 2024 [1]

（来源：华为中国政企业务） 近年来，国家持续推进医疗数智化与县域医共体建设，为行业发展划定清晰航向。2025年3月《关于印发紧密型县域医共体信息化功能指引的通知》正式 发布，《通知》中明确提出："推进人工智能、大数据、互联网、5G等新一代信息技术应用，全面提升紧密型县域医共体数字服务和治理能力，充分发挥 紧密型县域医共体的体制优势及信息化支撑作用。" 来源：市场资讯 在政策推动下，从三甲医院的精细化运营到县域医共体的资源整合，医疗行业对算力支撑、网络传输、场景适配的需求日益迫切。华为依托Atlas系列AI 算力底座、鲲鹏920新产品及星河AI数据中心网络，为这些场景的落地提供了更加坚实的技术底座，为医疗数智化提供了有力支撑。 针对政策导向与行业现状，华为深知医疗场景的复杂性与多样性，在"2025华为商业市场秋季产品方案发布会"上正式推出"3+18"重磅产品方案，其中医院 AI电子病历一体机、星河AI高品质医院网络、县域医共体解决方案，精准响应分级诊疗与智能升级需求，为多层级医院提供可落地的数智化路径。 多场景方案矩阵， 适配不同规模医院的差异化需求 医疗数智化需因院施策，实现"大小医院皆可享"。对于综合性三甲 ...

Core Insights - Shenzhen People's Hospital and Huawei signed a cooperation framework agreement to build an AI hospital and a smart "one hospital multiple zones" system, aiming to enhance the digital intelligence level of the hospital and set a benchmark for smart hospitals in China [1][3] Group 1: Partnership Details - The signing marks a new phase of collaboration, focusing on strengthening digital infrastructure, building AI hospitals, and creating a self-innovative smart medical technology application demonstration benchmark [3] - Huawei's medical division highlighted its global leading technology advantages in AI system architecture and engineering capabilities, emphasizing the transformation of technology into clinical value [3] Group 2: Technological Innovations - A distributed handheld AI ultrasound system based on 5.5G network was launched, integrating 5.5G, cloud storage, cloud computing, and AI large model technology, aimed at solving the "last mile" issue in grassroots diagnosis and treatment [5] - The system features zero latency and high reliability for real-time transmission of high-quality ultrasound images, with built-in AI algorithms for automatic identification of lesions and normal tissues, enhancing diagnostic efficiency and quality [5] Group 3: Future Directions - Huawei will focus on the needs of Shenzhen People's Hospital to further integrate AI and big data into hospital information construction, aiming to create a high-level smart hospital model that serves the Greater Bay Area and the global market [5]

Group 1 - China-based medical device manufacturer Mindray Medical (300760.SZ) plans a secondary listing in Hong Kong, aiming to raise at least $1 billion, with Huatai Securities and JPMorgan preparing the stock issuance [1] - Mindray Medical is a leading global supplier of medical devices and solutions, boasting the most comprehensive product line among domestic peers, with products like monitors, anesthesia machines, ventilators, defibrillators, blood cell analyzers, and ultrasound systems ranking in the top three globally [1] - The company's medical ecosystem is continuously deepening in clinical applications, with plans to launch the Qiyuan Critical Care Model in 2024, which is expected to expand into emergency, anesthesia, imaging, and laboratory departments, fully integrating digital intelligence in areas such as assisted diagnosis, report generation and review, clinical case studies, knowledge retrieval, and teaching research [1]

Core Viewpoint - China-based medical device manufacturer Mindray Medical (300760.SZ) plans to conduct a secondary listing in Hong Kong, aiming to raise at least $1 billion, with Huatai Securities and JPMorgan involved in the stock issuance process [1] Company Overview - Mindray Medical is a leading global supplier of medical devices and solutions, boasting the most comprehensive product line among domestic peers, including monitors, anesthesia machines, ventilators, defibrillators, blood cell analyzers, and ultrasound devices, all ranking in the top three in global market share [1] Product Development - The company is deepening its medical ecosystem focused on critical care, with plans to launch the Qiyuan Critical Care Model in 2024, which is expected to expand into emergency, anesthesia, imaging, and laboratory departments, applying digital intelligence across various fields such as assisted diagnosis, report generation and review, clinical case studies, knowledge retrieval, and teaching research [1]